Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. HOOD
9. MU
10. IBM

Go back to Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
(NASDAQ: IONS) Delayed: 75.89 +1.77 (2.39%)
Previous Close $74.12    52 Week High $62.68 
Open $74.85    52 Week Low $19.59 
Day High $76.56    P/E N/A 
Day Low $74.12    EPS $0.00 
Volume 1,956,125